More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 weeks of ...

In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...

More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of starting ...

The "Janus Kinase (JAK) Inhibitor - Pipeline Insight, 2025" drug pipelines has been added to ResearchAndMarkets.com's offering.The "Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025" report ...

Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

Janus kinase inhibitor cycling may be more effective than switching to bDMARDs among patients with RA who had an inadequate response to initial JAK inhibitor therapy.

As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...

JAK inhibitor treatment is associated with a reduction in risk of thromboembolic events for patients with myeloproliferative neoplasms. Treatment with Janus kinase inhibitors (JAKis) has been found to ...

The reduction in itch was the greatest contributor to quality-of-life improvement for adolescents and adults with atopic ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...